Home of the BSi NeuroTranslational Drug Discovery Program
The BSi NeuroTranslational Drug Discovery Program was created with the mission of identifying novel drug targets arising from JHU faculty’s research and translating them into new drug therapies for neurological disorders. To accomplish this, BSi has taken the practical approach of complementing Hopkins’ strengths in basic research with seasoned pharmaceutical professionals who have decades of experience in drug discovery and early stage development.
The BSi NeuroTranslational Drug Discovery staff has expertise in medicinal chemistry, assay development, drug metabolism and pharmacokinetics, animal pharmacology/ toxicology, the conduct of preclinical studies, and the knowledge necessary to bring novel drugs to the clinic. The BSi NeuroTranslational Drug Discovery Program’s scientists will work hand-in-hand with faculty interested in translational medicine to create dedicated, multidisciplinary project teams. These teams will work collaboratively to obtain funding and progress targets through the drug discovery and preclinical development process. The data packages arising from this work will enhance out licensing and new venture opportunities. Raising the bar of medical excellence through an interdisciplinary education is a hallmark of the Johns Hopkins community. The BSi NeuroTranslational Drug Discovery core staff, with breadth of industrial pharmaceutical expertise, will also participate in this tradition by providing drug discovery educational opportunities for faculty, staff, and students at Hopkins. The staff is also engaged in teaching a national 1-week course for academic scientists called 'Training in Neurotherapeutics Discovery and Development" in February each year in Washington DC, and has initiated a new National Academic Drug Discovery Consortium to bring together the increasing number of academic scientists in the US engaged in translational research.
